Repurposing Antimalarials to Tackle the COVID-19 Pandemic

Sanjeev Krishna; Yolanda Augustin; Jigang Wang; Chengchao Xu; Henry M. Staines; Hans Platteeuw; Adeeba Kamarulzaman; Amadou Sall; Peter Kremsner

doi:10.1016/j.pt.2020.10.003

Repurposing Antimalarials to Tackle the COVID-19 Pandemic

Sanjeev Krishna, Yolanda Augustin, Jigang Wang, Chengchao Xu, Henry M. Staines, Hans Platteeuw, Adeeba Kamarulzaman, Amadou Sall, Peter Kremsner

Research output: Contribution to journal › Short Survey › Other › peer-review

53 Citations (Scopus)

Abstract

Artemisinin-based combination therapies (ACTs) have demonstrated in vitro inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Artemisinins have also shown anti-inflammatory effects, including inhibition of interleukin-6 (IL-6) that plays a key role in the development of severe coronavirus disease 2019 (COVID-19). There is now sufficient evidence for the effectiveness of ACTs, and in particular artesunate/pyronaridine, to support clinical studies for COVID-19 infections.

Original language	English
Pages (from-to)	8-11
Number of pages	4
Journal	Trends in Parasitology
Volume	37
Issue number	1
DOIs	https://doi.org/10.1016/j.pt.2020.10.003
Publication status	Published - Jan 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

antimalarial
antiviral
artesunate/pyronaridine
cytokine storm
drug repurposing
SARS-CoV-2

Access to Document

10.1016/j.pt.2020.10.003

Cite this

@article{c522c6bbcf1b431faa9a9edbcd6dd37f,

title = "Repurposing Antimalarials to Tackle the COVID-19 Pandemic",

abstract = "Artemisinin-based combination therapies (ACTs) have demonstrated in vitro inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Artemisinins have also shown anti-inflammatory effects, including inhibition of interleukin-6 (IL-6) that plays a key role in the development of severe coronavirus disease 2019 (COVID-19). There is now sufficient evidence for the effectiveness of ACTs, and in particular artesunate/pyronaridine, to support clinical studies for COVID-19 infections.",

keywords = "antimalarial, antiviral, artesunate/pyronaridine, cytokine storm, drug repurposing, SARS-CoV-2",

author = "Sanjeev Krishna and Yolanda Augustin and Jigang Wang and Chengchao Xu and Staines, \{Henry M.\} and Hans Platteeuw and Adeeba Kamarulzaman and Amadou Sall and Peter Kremsner",

note = "Funding Information: H.M.S. is supported by the Wellcome Trust Institutional Strategic Support Fund ( 204809/Z/16/Z ) awarded to St George{\textquoteright}s University of London . Funding Information: H.M.S. is supported by the Wellcome Trust Institutional Strategic Support Fund (204809/Z/16/Z) awarded to St George's University of London. Publisher Copyright: {\textcopyright} 2020",

year = "2021",

month = jan,

doi = "10.1016/j.pt.2020.10.003",

language = "English",

volume = "37",

pages = "8--11",

journal = "Trends in Parasitology",

issn = "1471-4922",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Repurposing Antimalarials to Tackle the COVID-19 Pandemic

AU - Krishna, Sanjeev

AU - Augustin, Yolanda

AU - Wang, Jigang

AU - Xu, Chengchao

AU - Staines, Henry M.

AU - Platteeuw, Hans

AU - Kamarulzaman, Adeeba

AU - Sall, Amadou

AU - Kremsner, Peter

N1 - Funding Information: H.M.S. is supported by the Wellcome Trust Institutional Strategic Support Fund ( 204809/Z/16/Z ) awarded to St George’s University of London . Funding Information: H.M.S. is supported by the Wellcome Trust Institutional Strategic Support Fund (204809/Z/16/Z) awarded to St George's University of London. Publisher Copyright: © 2020

PY - 2021/1

Y1 - 2021/1

N2 - Artemisinin-based combination therapies (ACTs) have demonstrated in vitro inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Artemisinins have also shown anti-inflammatory effects, including inhibition of interleukin-6 (IL-6) that plays a key role in the development of severe coronavirus disease 2019 (COVID-19). There is now sufficient evidence for the effectiveness of ACTs, and in particular artesunate/pyronaridine, to support clinical studies for COVID-19 infections.

AB - Artemisinin-based combination therapies (ACTs) have demonstrated in vitro inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Artemisinins have also shown anti-inflammatory effects, including inhibition of interleukin-6 (IL-6) that plays a key role in the development of severe coronavirus disease 2019 (COVID-19). There is now sufficient evidence for the effectiveness of ACTs, and in particular artesunate/pyronaridine, to support clinical studies for COVID-19 infections.

KW - antimalarial

KW - antiviral

KW - artesunate/pyronaridine

KW - cytokine storm

KW - drug repurposing

KW - SARS-CoV-2

UR - https://www.scopus.com/pages/publications/85096379066

U2 - 10.1016/j.pt.2020.10.003

DO - 10.1016/j.pt.2020.10.003

M3 - Short Survey

C2 - 33153922

AN - SCOPUS:85096379066

SN - 1471-4922

VL - 37

SP - 8

EP - 11

JO - Trends in Parasitology

JF - Trends in Parasitology

IS - 1

ER -

Repurposing Antimalarials to Tackle the COVID-19 Pandemic

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Erratum: “Repurposing Antimalarials to Tackle the COVID-19 Pandemic” (Trends in Parasitology (2021) 37(1) (8–11), (S1471492220302889), (10.1016/j.pt.2020.10.003))

Cite this